{{Drugbox
| IUPAC_name = 1-[(2''R'')-3,4-dihydro-2''H''-chromen-2-yl]-''N''-([5-(4-fluorophenyl)pyridin-3-yl]methyl)methanamine
| image = Sarizotan.png

<!--Clinical data-->
| tradename =  
| pregnancy_category = N/A
| legal_status = Discontinued
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 177975-08-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 6918388
| ChemSpiderID = 2319847
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 467LU0UCUW

<!--Chemical data-->
| C=22 | H=21 | F=1 | N=2 | O=1 
| molecular_weight = 348.413 g/mol
| smiles = C1CC2=CC=CC=C2O[C@H]1CNCC3=CN=CC(=C3)C4=CC=C(C=C4)F
}}

'''Sarizotan''' ('''EMD-128,130''') is a [[binding selectivity|selective]] [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[agonist]] and [[Dopamine receptor D2|D<sub>2</sub> receptor]] [[antagonist (pharmacology)|antagonist]],<ref>{{Cite journal
| doi = 10.1177/026988110201600301
| pmid = 12236624
| year = 2002
| last1 = Rabiner | first1 = E. A.
| last2 = Gunn | first2 = R. N.
| last3 = Wilkins | first3 = M. R.
| last4 = Sedman | first4 = E.
| last5 = Grasby | first5 = P. M.
| title = Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with 11CWAY-100635 and 11Craclopride
| volume = 16
| issue = 3
| pages = 195–199
| journal = Journal of psychopharmacology (Oxford, England)
}}</ref> which has [[antipsychotic]] effects,<ref>{{Cite journal
| doi = 10.1124/jpet.105.087163
| pmid = 15987834
| year = 2005
| last1 = Assié | first1 = M.
| last2 = Ravailhe | first2 = V.
| last3 = Faucillon | first3 = V.
| last4 = Newman-Tancredi | first4 = A.
| title = Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain
| volume = 315
| issue = 1
| pages = 265–272
| journal = The Journal of Pharmacology and Experimental Therapeutics 
}}</ref><ref>{{Cite journal
| doi = 10.1007/s00213-007-0762-7
| pmid = 17393144
| year = 2007
| last1 = Auclair | first1 = A.
| last2 = Galinier | first2 = A.
| last3 = Besnard | first3 = J.
| last4 = Newman-Tancredi | first4 = A.
| last5 = Depoortère | first5 = R.
| title = Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats
| volume = 193
| issue = 1
| pages = 45–54
| journal = Psychopharmacology 
}}</ref> and has also shown efficacy in reducing [[dyskinesia]]s resulting from long-term [[Parkinson's disease#Treatment|anti-Parkinsonian]] treatment with [[levodopa]].<ref>{{Cite journal
| pmid = 11723272
| year = 2001
| last1 = Bibbiani | first1 = F.
| last2 = Oh | first2 = J. D.
| last3 = Chase | first3 = T. N.
| title = Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
| volume = 57
| issue = 10
| pages = 1829–1834
| journal = Neurology
 | doi=10.1212/wnl.57.10.1829
}}</ref><ref>{{Cite journal
| doi = 10.1007/s00702-003-0094-7
| pmid = 14767715
| year = 2004
| last1 = Bartoszyk | first1 = G.
| last2 = Van Amsterdam | first2 = C.
| last3 = Greiner | first3 = H.
| last4 = Rautenberg | first4 = W.
| last5 = Russ | first5 = H.
| last6 = Seyfried | first6 = C.
| title = Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile
| volume = 111
| issue = 2
| pages = 113–126
| journal = Journal of neural transmission (Vienna, Austria : 1996) 
}}</ref><ref>{{Cite journal
| doi = 10.1002/mds.20370
| pmid = 15791634
| year = 2005
| last1 = Bara-Jimenez | first1 = W.
| last2 = Bibbiani | first2 = F.
| last3 = Morris | first3 = M.
| last4 = Dimitrova | first4 = T.
| last5 = Sherzai | first5 = A.
| last6 = Mouradian | first6 = M.
| last7 = Chase | first7 = T.
| title = Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease
| volume = 20
| issue = 8
| pages = 932–936
| journal = Movement disorders : official journal of the Movement Disorder Society 
}}</ref><ref>{{Cite journal
| doi = 10.1016/j.parkreldis.2008.11.001
| pmid = 19196540
| year = 2009
| last1 = Grégoire | first1 = L.
| last2 = Samadi | first2 = P.
| last3 = Graham | first3 = J.
| last4 = Bédard | first4 = P.
| last5 = Bartoszyk | first5 = G.
| last6 = Di Paolo | first6 = T.
| title = Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys
| volume = 15
| issue = 6
| pages = 445–452
| journal = Parkinsonism & related disorders 
}}</ref>

In June 2006, the developer [[Merck KGaA]] announced that the development of sarizotan was discontinued, after two sarizotan Phase III studies (PADDY I, PADDY II) failed to meet the primary efficacy endpoint and neither the Phase II findings nor the results from preclinical studies could be confirmed. No statistically significant difference of the primary target variable between sarizotan and placebo could be demonstrated.<ref>{{cite news|url=http://www.ad-hoc-news.de/dgap-adhoc-merck-kgaa-development-of-sarizotan-to-treat--/de/News/7492546|title=Merck KGaA: Development of Sarizotan to treat Parkinson's patients will not be pursued|date=23 June 2006|publisher=Ad Hoc News}}</ref><ref>{{cite news|url=https://www.forbes.com/feeds/afx/2006/06/23/afx2835559.html|title=Merck KGaA discontinues development of Parkinson drug Sarizotan UPDATE|date=23 June 2006|publisher=Forbes}}</ref>

== See also ==
* [[Osemozotan]]
* [[Piclozotan]]
* [[Robalzotan]]

== References ==
{{Reflist}}


{{Antipsychotics}}
{{Antiparkinsonian}}
{{Dopaminergics}}
{{Serotonergics}}

[[Category:Amines]]
[[Category:Pyridines]]
[[Category:Fluoroarenes]]
[[Category:Chromanes]]
[[Category:Abandoned drugs]]
{{nervous-system-drug-stub}}